220 related articles for article (PubMed ID: 36007113)
1. Unprecedented Chiral Nanovaccines for Significantly Enhanced Cancer Immunotherapy.
Liu H; Xie Z; Zheng M
ACS Appl Mater Interfaces; 2022 Sep; 14(35):39858-39865. PubMed ID: 36007113
[TBL] [Abstract][Full Text] [Related]
2. Engineered fluorescent carbon dots as promising immune adjuvants to efficiently enhance cancer immunotherapy.
Luo L; Liu C; He T; Zeng L; Xing J; Xia Y; Pan Y; Gong C; Wu A
Nanoscale; 2018 Nov; 10(46):22035-22043. PubMed ID: 30452049
[TBL] [Abstract][Full Text] [Related]
3. Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.
Li N; Zhang Y; Han M; Liu T; Wu J; Xiong Y; Fan Y; Ye F; Jin B; Zhang Y; Sun G; Sun X; Dong Z
Sci China Life Sci; 2024 Apr; 67(4):680-697. PubMed ID: 38206438
[TBL] [Abstract][Full Text] [Related]
4. Carbon Dots and Tumor Antigen Conjugates as Nanovaccines for Elevated Cancer Immunotherapy.
Liu H; Xie Z; Zheng M
Small; 2023 Aug; 19(31):e2206683. PubMed ID: 36978241
[TBL] [Abstract][Full Text] [Related]
5. Chiral polypeptide nanoparticles as nanoadjuvants of nanovaccines for efficient cancer prevention and therapy.
Su Y; Xu W; Wei Q; Ma Y; Ding J; Chen X
Sci Bull (Beijing); 2023 Feb; 68(3):284-294. PubMed ID: 36732117
[TBL] [Abstract][Full Text] [Related]
6. Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy.
Zhang X; Wang K; Zhao Z; Shan X; Wang Y; Feng Z; Li B; Luo C; Chen X; Sun J
ACS Nano; 2024 Mar; 18(9):7136-7147. PubMed ID: 38407021
[TBL] [Abstract][Full Text] [Related]
7. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy.
Niu L; Miao Y; Cao Z; Wei T; Zhu J; Li M; Bai B; Chen L; Liu N; Pan F; Zhu J; Wang C; Yang Y; Chen Q
ACS Nano; 2024 Jan; 18(4):3349-3361. PubMed ID: 38230639
[TBL] [Abstract][Full Text] [Related]
8. Nanovaccines: Merits, and diverse roles in boosting antitumor immune responses.
Yin Q; Wang Y; Xiang Y; Xu F
Hum Vaccin Immunother; 2022 Nov; 18(6):2119020. PubMed ID: 36170662
[TBL] [Abstract][Full Text] [Related]
9. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy.
Li R; Hao Y; Pan W; Wang W; Min Y
Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924
[TBL] [Abstract][Full Text] [Related]
10. Biologically Self-Assembled Tumor Cell-Derived Cancer Nanovaccines as an All-in-One Platform for Cancer Immunotherapy.
Liang K; Sun Y; Xie L; Liu Y; You Y; Xu J; Ma F; Huang Y; Song Q; Xiao W; Huang J; Gao X; Chen J
ACS Nano; 2024 Feb; 18(8):6702-6717. PubMed ID: 38359389
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of TLR7/8 Agonist-Conjugated Antigen Nanoparticles for Cancer Immunotherapy.
Wang N; Zhang G; Zhang P; Zhao K; Tian Y; Cui J
Adv Healthc Mater; 2023 Sep; 12(22):e2300249. PubMed ID: 37016572
[TBL] [Abstract][Full Text] [Related]
12. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy.
Xu J; Lv J; Zhuang Q; Yang Z; Cao Z; Xu L; Pei P; Wang C; Wu H; Dong Z; Chao Y; Wang C; Yang K; Peng R; Cheng Y; Liu Z
Nat Nanotechnol; 2020 Dec; 15(12):1043-1052. PubMed ID: 33139933
[TBL] [Abstract][Full Text] [Related]
13. Multi-signaling pathway activation by pH responsive manganese particles for enhanced vaccination.
Lv X; Huang J; Min J; Wang H; Xu Y; Zhang Z; Zhou X; Wang J; Liu Z; Zhao H
J Control Release; 2023 May; 357():109-119. PubMed ID: 36738971
[TBL] [Abstract][Full Text] [Related]
14. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
Yip T; Qi X; Yan H; Chang Y
ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
[TBL] [Abstract][Full Text] [Related]
15. In vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity.
Villegas-Mendez A; Garin MI; Pineda-Molina E; Veratti E; Bueren JA; Fender P; Lenormand JL
Mol Ther; 2010 May; 18(5):1046-53. PubMed ID: 20179681
[TBL] [Abstract][Full Text] [Related]
16. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy.
Zhou S; Huang Y; Chen Y; Liu S; Xu M; Jiang T; Song Q; Jiang G; Gu X; Gao X; Chen J
Biomaterials; 2020 Mar; 235():119795. PubMed ID: 32014739
[TBL] [Abstract][Full Text] [Related]
17. Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy.
Dong Y; Gao J; Pei M; Wang X; Zhang C; Du Y; Jiang Y
Int J Nanomedicine; 2020; 15():2685-2697. PubMed ID: 32368049
[TBL] [Abstract][Full Text] [Related]
18. Carrier-free subunit nanovaccine amplifies immune responses against tumors and viral infections.
Chen H; Li Y; Li L; Yang Z; Wen Z; Liu L; Liu H; Chen Y
Acta Biomater; 2023 Mar; 158():525-534. PubMed ID: 36572250
[TBL] [Abstract][Full Text] [Related]
19. A natural IgM hitchhiking strategy for delivery of cancer nanovaccines to splenic marginal zone B cells.
Wang H; Wu X; Sun Y; Liu A; He Y; Xu Z; Lu Y; Zhan C
J Control Release; 2024 Apr; 368():208-218. PubMed ID: 38395156
[TBL] [Abstract][Full Text] [Related]
20. Endogenous/Exogenous Nanovaccines Synergistically Enhance Dendritic Cell-Mediated Tumor Immunotherapy.
Zhang Y; Li Q; Ding M; Xiu W; Shan J; Yuwen L; Yang D; Song X; Yang G; Su X; Mou Y; Teng Z; Dong H
Adv Healthc Mater; 2023 Jul; 12(17):e2203028. PubMed ID: 36807733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]